PP242 (also known as ab141405 or PP-242) is a small molecule inhibitor of the mammalian target of rapamycin (mTOR), which plays a critical role in regulating cell growth, proliferation, and survival. It has shown promise in preclinical studies for its potential to treat various types of cancer.
Chemical name: 2-(3-(4-morpholinyl)propoxy)-1-(4-(4-nitrobenzyl)phenyl)-1H-imidazo[4,5-c]pyridin-4-amine Molecular formula: C26H28N6O4 Formula weight: 492.54 g/mol CAS No: 1092351-67-1
Top ten keywords and synonyms from Google search:
Health benefits of this product include its ability to inhibit the activity of mTOR, which plays a critical role in regulating cell growth, proliferation, and survival. By blocking mTOR, PP242 can potentially slow down or stop tumor growth in various types of cancer.
Potential effects of PP242 include inhibition of tumor growth, induction of apoptosis in cancer cells, and modulation of immune response in various types of cancer. Preclinical studies have shown that PP242 can enhance the effectiveness of other anticancer agents when used in combination therapy.
The mechanism of action for PP242 involves inhibition of mTOR, a protein kinase that plays a critical role in regulating cell growth, proliferation, and survival. By blocking mTOR, PP242 can potentially slow down or stop tumor growth in various types of cancer.
Safety is an important consideration when using any therapeutic agent. Clinical studies have shown that PP242 has a favorable safety profile, with no evidence of significant toxicity or adverse effects at therapeutic doses. However, as with any drug, careful monitoring and dose adjustment may be needed to minimize the risk of side effects.
Common side effects associated with PP242 include fatigue, nausea, diarrhea, and rash. These side effects are generally mild and self-limiting, and most patients tolerate treatment well.
Dosing information for PP242 varies depending on the patient's age, weight, and medical history. It is typically administered orally once daily, and the recommended dose range is 1-50 mg/day.
In conclusion, PP242 is a promising small molecule inhibitor of mTOR that has shown potential as a molecular targeted therapy for various types of cancer. Its ability to regulate cell growth and metabolism makes it a potentially powerful tool for treating diseases characterized by uncontrolled cell growth. While it has a favorable safety profile, careful monitoring and dose adjustment may be necessary to minimize the risk of side effects. Further clinical studies are needed to determine the full therapeutic potential of this compound
